MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts

TH-302 is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. It is currently being evaluated in clinical trials, including two trials in Pancreatic Ductal Adenocarcinomas (PDAC). The current study was undertaken to evaluate imaging...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:PLoS One
Prif Awduron: Zhang, Xiaomeng, Wojtkowiak, Jonathan W., Martinez, Gary V., Cornnell, Heather H., Hart, Charles P., Baker, Amanda F., Gillies, Robert
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Public Library of Science 2016
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4882075/
https://ncbi.nlm.nih.gov/pubmed/27227903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0155289
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg